This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance. The main goal is to see if BLX-0871 is safe and well tolerated when given to healthy adults. The study will also measure how the body processes BLX-0871, including how quickly it is absorbed, how long it stays in the blood, and how it is eliminated. Another objective is to see whether food affects the absorption of BLX-0871. It will also look at how the drug affects the body by looking at markers of AMPK activity.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants who experienced Adverse Events (AEs)
Timeframe: From first dose through End of Study (up to ~28 days per participant)
Number of participants who experienced Serious Adverse Events (SAEs)
Timeframe: From first dose through End of Study (up to ~28 days per participant)
Number of participants who experienced Treatment-Related Adverse Avents (TRAEs)
Timeframe: From first dose through End of Study (up to ~28 days per participant)